Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Acquisitions & Divestments: 2015-2025

Historic Change in Acquisitions & Divestments for Iovance Biotherapeutics (IOVA) over the last 6 years, with Sep 2025 value amounting to $120.0 million.

  • Iovance Biotherapeutics' Change in Acquisitions & Divestments rose 9.09% to $120.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $446.0 million, marking a year-over-year increase of 27.43%. This contributed to the annual value of $428.0 million for FY2024, which is 49.87% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Change in Acquisitions & Divestments of $120.0 million as of Q3 2025, which was up 33.33% from $90.0 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Change in Acquisitions & Divestments high stood at $164.4 million for Q1 2023, and its period low was $20.9 million during Q3 2023.
  • For the 3-year period, Iovance Biotherapeutics' Change in Acquisitions & Divestments averaged around $94.9 million, with its median value being $110.0 million (2024).
  • Data for Iovance Biotherapeutics' Change in Acquisitions & Divestments shows a peak YoY increase of 425.06% (in 2024) and a maximum YoY decrease of 47.07% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $38.0 million in 2023, then spiked by 205.26% to $116.0 million in 2024, then grew by 9.09% to $120.0 million in 2025.
  • Its last three reported values are $120.0 million in Q3 2025, $90.0 million for Q2 2025, and $120.0 million during Q1 2025.